Compare PRTS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | EDSA |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 51.5M |
| IPO Year | 2006 | 2018 |
| Metric | PRTS | EDSA |
|---|---|---|
| Price | $8.46 | $1.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.00 | ★ $16.33 |
| AVG Volume (30 Days) | 28.9K | ★ 2.9M |
| Earning Date | 10-29-2026 | 12-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $0.72 |
| 52 Week High | $10.98 | $20.32 |
| Indicator | PRTS | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 32.72 |
| Support Level | $7.76 | $0.72 |
| Resistance Level | $8.69 | $6.62 |
| Average True Range (ATR) | 0.71 | 0.36 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 92.17 | 5.53 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. Its products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.